

Media Release

Zug, 3 January 2022

Ad hoc announcement pursuant to Art. 53 Listing Rules

HBM Healthcare Investments delivers strong return despite weak biotech sector and increases net asset value per share (NAV) by 19 percent in calendar year 2021

HBM Healthcare Investments closes the 2021 calendar year with another strong performance. The net asset value per share (NAV) rose by 19 percent to CHF 336.27 as at 31 December 2021, while the share price increased by 15.2 percent to close at CHF 339.00 at a small premium to NAV.

The healthcare sector showed a mixed picture in terms of performance. While the large-cap pharmaceutical companies (MSCI World Healthcare Index +23.9 percent, measured in Swiss francs) rose strongly in value, biotech companies (Nasdaq Biotechnology Index +3.0% and SPDR S&P Biotech ETF -18.1%) took a breather after their good run in recent years.

HBM Healthcare Investments, which is mainly invested in the segment of small and medium sized biotech companies, was able to more than compensate for the significant share price declines in this segment thanks to the strong share price performance of its largest listed investment, the Chinese Cathay Biotech (share price +118%), value contributions from the portfolio of private companies (financing rounds and IPOs), and partial profit realisations in the portfolio of listed companies.

Expected net profit of around CHF 275 million for the first 9 months of the financial year 2021/2022

Also for the first 9 months of the financial year 2021/2022 ending on 31 March, there was an increase in value of 12.8 percent in the NAV and of 5.7 percent in the share price (MSCI World Health Care Index +15.4%, NBI -2.7%, XBI -20.2%). Based on the reported NAV as at 31 December 2021, HBM Healthcare Investments expects a net profit of approximately CHF 275 million for this period (previous year net profit of CHF 644.6 million). In the case of an investment company, the net result reflects the changes in the value of the investments held.

The present figures are preliminary based on the current status of the financial closing process. The final result will be published with the December 2021 quarterly report on 21 January 2022.

Contact

For further information, please contact Dr. Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

HBM Healthcare Investments Ltd.

Bundesplatz 1 CH-6300 Zug | Phone: +41 41 710 75 77 | info@hbmhealthcare.com | www.hbmhealthcare.com

Follow us on Twitter: [@HbmHealthcare](https://twitter.com/HbmHealthcare)

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to US persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments AG's securities were not issued in accordance with the U.S. U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions.